This Will Save Us Years – Lean LaunchPad for Life Sciences

    Part 1 of this post described the issues in the drug discovery.  Part 2 covered medical devices and digital health. Part 3  described what we’re going to do about it. This is post is a brief snapshot of our progress. Vitruvian is one of the 28 teams in the class. The team members are:
    • Dr. Hobart Harris  Chief of  General Surgery, Vice-Chair of the Department of Surgery, and a Professor of Surgery at  UCSF. Dr. Harris is also a Principal Investigator in the UCSF Surgical Research Laboratory at San Francisco General Hospital.
    • Dr. David Young,  Professor of Plastic Surgery at UCSF. His area of expertise includes wound healing, microsurgery, and reconstruction after burns and trauma. His research interests include the molecular mechanisms of wound healing and the epidemiology and treatment of soft tissue infections.
    • Sarah Seegal is at One Medical Sarah is interested in increasing the quality and accessibility of healthcare services. Sarah worked with to connect individuals with professional therapists for online sessions.
    • Cindy Chang is a Enzymologist investigating novel enzymes involved in biofuel and chemical synthesis in microbes at LS9

    Vitruvian’s first product, MyoSeal, promotes wound repair via biocompatible microparticles plus a fibrin tissue sealant that has been shown to prevent incisional hernias through enhanced wound healing.  The team believed that surgeons would embrace the product and pay thousands to use it.  In week 2 of the class 14 of their potential customers (surgeons) told the team otherwise. Watch this 90 second clip and find out how the Lean LaunchPad class saved them years.

    Vitruvian Therapeutics - Week 2 from Ralph Guggenheim on Vimeo.

    Originally posted on and reproduced here with the author's permission.